Maxim Sees Major Upside In These Biotech Stocks
In a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here's a rundown of what they had to say.
Athersys, Inc. (NASDAQ: ATHX)
Analysts believe that Athersys may have found a "sweet spot" for stroke treatment timing, as data from a phase II trial of MultiStem treatment one to two days after a stroke event is expected soon. Maxim has a Buy rating on Athersys and a $9.00 target for the stock.
Cytori Therapeutics Inc (NASDAQ: CYTX)
Cytori recently announced an emphasis on cost-cutting initiatives as it moves forward with its adipose-derives regenerative cell (ADRC) treatment trials. Analysts see big potential for the company in the scleroderma treatment space. Maxim has a Buy rating on Cytori and a $7.00 price target for the stock.
Ocata Therapeutics Inc (OTC: OCAT)
Analysts like the fundamental science and technology that Ocata brings to the table, but they are concerned about the near-term funding risk the company faces after it failed to close a $50 million funding raise in late 2014. Maxim has a Hold rating on Ocata.
OncoSec Medical Inc (OTC: ONCS)
Analysts like the results that OncoSec has seen so far in using up regulation of IL12 to drive cytotoxic T cells to attack tumors. Maxim has a Buy rating on OncoSec and a $3.00 target for the stock.
Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)
Maxim believes that the company is undervalued following its merger with OnCor. Maxim's Buy rating and $27.00 price target for Tekmira is based on an average of sum-of-the-parts, free cash flow and discounted cash flow valuation models.
Latest Ratings for ATHX
|Feb 2017||Needham||Initiates Coverage On||Buy|
|Apr 2014||First Analysis||Initiates Coverage on||Overweight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.